Andrew A Wagner1, Philip J Cheng2, Arie Carneiro3, Ostap Dovirak4, Arjun Khosla5, Kimberly N Taylor5, Catrina M Crociani5, Kyle C McAnally5, Andrew Percy6, Lauren E Dewey5, Martin G Sanda7, Peter Chang8. 1. Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. 2. Harvard Longwood Program in Urology, Boston, Massachusetts. 3. Hospital Israelita Albert Einstein and ABC Medical School, São Paolo, Brazil. 4. Virginia Beach, Virginia. 5. Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts. 6. Virginia Commonwealth University School of Medicine, Richmond, Virginia. 7. Emory University School of Medicine, Atlanta, Georgia. 8. Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: pchang@bidmc.harvard.edu.
Abstract
PURPOSE: EPIC-CP (Expanded Prostate Cancer Index Composite for Clinical Practice) is a short questionnaire that comprehensively measures patient reported health related quality of life at the point of care. We evaluated the feasibility of using EPIC-CP in the routine clinical care of patients with prostate cancer without research infrastructure. We compared longitudinal patient and practitioner reported prostate cancer outcomes. MATERIALS AND METHODS: We reviewed health related quality of life outcomes in 482 patients who underwent radical prostatectomy at our institution from 2010 to 2014. EPIC-CP was administered and interpreted in routine clinical practice without research personnel. We compared practitioner documented rates of incontinence pad use and functional erections to patient reported rates using EPIC-CP. RESULTS: A total of 708 EPIC-CP questionnaires were completed. Mean urinary incontinence domain scores were significantly higher (worse) than baseline (mean ± SD 0.6 ± 0.2) 3 and 6 months after treatment (mean 3.1 ± 2.3 and 2.2 ± 2.1, respectively, each p <0.05) but they returned to baseline at 12 months (mean 1.6 ± 1.7, p >0.05). Mean sexual domain scores were significantly worse than baseline (mean 2.4 ± 2.8) at all posttreatment time points (each p <0.05). Practitioners significantly overestimated incontinence pad-free rates at 3 months (48% vs 39%) and functional erection rates at 3 months (18% vs 12%), 6 months (38% vs 23%) and 12 months (45% vs 23%, each p <0.05). CONCLUSIONS: EPIC-CP is feasible to use in the routine clinical care of patients with prostate cancer without requiring a research infrastructure. Using EPIC-CP in clinical practice may help practitioners objectively assess and appropriately manage posttreatment side effects in patients with prostate cancer. Copyright Â
PURPOSE:EPIC-CP (Expanded Prostate Cancer Index Composite for Clinical Practice) is a short questionnaire that comprehensively measures patient reported health related quality of life at the point of care. We evaluated the feasibility of using EPIC-CP in the routine clinical care of patients with prostate cancer without research infrastructure. We compared longitudinal patient and practitioner reported prostate cancer outcomes. MATERIALS AND METHODS: We reviewed health related quality of life outcomes in 482 patients who underwent radical prostatectomy at our institution from 2010 to 2014. EPIC-CP was administered and interpreted in routine clinical practice without research personnel. We compared practitioner documented rates of incontinence pad use and functional erections to patient reported rates using EPIC-CP. RESULTS: A total of 708 EPIC-CP questionnaires were completed. Mean urinary incontinence domain scores were significantly higher (worse) than baseline (mean ± SD 0.6 ± 0.2) 3 and 6 months after treatment (mean 3.1 ± 2.3 and 2.2 ± 2.1, respectively, each p <0.05) but they returned to baseline at 12 months (mean 1.6 ± 1.7, p >0.05). Mean sexual domain scores were significantly worse than baseline (mean 2.4 ± 2.8) at all posttreatment time points (each p <0.05). Practitioners significantly overestimated incontinence pad-free rates at 3 months (48% vs 39%) and functional erection rates at 3 months (18% vs 12%), 6 months (38% vs 23%) and 12 months (45% vs 23%, each p <0.05). CONCLUSIONS:EPIC-CP is feasible to use in the routine clinical care of patients with prostate cancer without requiring a research infrastructure. Using EPIC-CP in clinical practice may help practitioners objectively assess and appropriately manage posttreatment side effects in patients with prostate cancer. Copyright Â
Authors: Mohannad A Awad; Luke Hallgarth; Ghassan A Barayan; Mohammed Shahait; Ramiz Abu-Hijlih; Ala'a Farkouh; Raed A Azhar; Musab M Alghamdi; Ahmad Bugis; Said Yaiesh; Saad Aldousari; Alaeddin Barham; Mohamed Saed; Ayman Moussa; Waleed Hassen; Shelly Naud; Mark K Plante; Richard Grunert Journal: Arab J Urol Date: 2021-11-28
Authors: Arie Carneiro; Willy Baccaglini; Felipe P A Glina; Paulo P Kayano; Victor M Nunes; Oren Smaletz; Wanderley Marques Bernardo; Icaro Thiago de Carvalho; Gustavo Caserta Lemos Journal: Int Braz J Urol Date: 2017 Jul-Aug Impact factor: 1.541
Authors: Adilson Edson Romanzini; Maria da Graça Pereira; Caroline Guilherme; Adauto José Cologna; Emilia Campos de Carvalho Journal: Rev Lat Am Enfermagem Date: 2018-09-03